Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Metabolism of Strained Rings: Glutathione S-transferase-Catalyzed Formation of a Glutathione-Conjugated Spiro-azetidine without Prior Bioactivation.

Li XQ, Grönberg G, Bangur EH, Hayes MA, Castagnoli N Jr, Weidolf L.

Drug Metab Dispos. 2019 Nov;47(11):1247-1256. doi: 10.1124/dmd.119.088658. Epub 2019 Sep 6.

PMID:
31492694
2.

Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane.

Li XQ, Hayes MA, Grönberg G, Berggren K, Castagnoli N Jr, Weidolf L.

Drug Metab Dispos. 2016 Aug;44(8):1341-8. doi: 10.1124/dmd.116.071142. Epub 2016 Jun 2.

PMID:
27256986
3.

Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice.

Crowley JJ, Ashraf-Khorassani M, Castagnoli N Jr, Sullivan PF.

Neurotoxicology. 2013 Dec;39:153-7. doi: 10.1016/j.neuro.2013.09.005. Epub 2013 Oct 6.

4.

Bioactivation of the cannabinoid receptor antagonist rimonabant to a cytotoxic iminium ion metabolite.

Foster AJ, Prime LH, Gustafsson F, Temesi DG, Isin EM, Midlöv J, Castagnoli N Jr, Kenna JG.

Chem Res Toxicol. 2013 Jan 18;26(1):124-35. doi: 10.1021/tx300418w. Epub 2012 Dec 12.

PMID:
23234359
5.

Identification of the metabolites of lesogaberan using linear trap quadrupole orbitrap mass spectrometry and hydrophilic interaction liquid chromatography.

Ekdahl A, Aurell-Holmberg A, Castagnoli N Jr.

Xenobiotica. 2013 May;43(5):461-7. doi: 10.3109/00498254.2012.725486. Epub 2012 Oct 3.

PMID:
23030741
6.

Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant.

Bergström MA, Isin EM, Castagnoli N Jr, Milne CE.

Drug Metab Dispos. 2011 Oct;39(10):1823-32. doi: 10.1124/dmd.111.039412. Epub 2011 Jul 6.

PMID:
21733882
7.

Reaction of benzophenone triplet with aliphatic amines. What a potent neurotoxin can tell us about the reaction mechanism.

Grimm ML, Allen WJ, Finn M, Castagnoli N Jr, Tanko JM.

Bioorg Med Chem. 2011 Feb 15;19(4):1458-63. doi: 10.1016/j.bmc.2011.01.002. Epub 2011 Jan 7.

PMID:
21277784
8.

Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.

Pretorius A, Ogunrombi MO, Fourie H, Terre'blanche G, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2010 Jun 1;18(11):4111-8. doi: 10.1016/j.bmc.2010.03.079. Epub 2010 Apr 3.

PMID:
20451395
9.

P450-catalyzed vs. electrochemical oxidation of haloperidol studied by ultra-performance liquid chromatography/electrospray ionization mass spectrometry.

Mali'n TJ, Weidolf L, Castagnoli N Jr, Jurva U.

Rapid Commun Mass Spectrom. 2010 May 15;24(9):1231-40. doi: 10.1002/rcm.4505.

PMID:
20391593
10.

Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues.

Strydom B, Malan SF, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2010 Feb;18(3):1018-28. doi: 10.1016/j.bmc.2009.12.064. Epub 2010 Jan 6.

PMID:
20093036
11.

Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.

Bonn B, Masimirembwa CM, Castagnoli N Jr.

Drug Metab Dispos. 2010 Jan;38(1):187-99. doi: 10.1124/dmd.109.028670.

PMID:
19797609
12.

Naphthoquinones and bioactive compounds from tobacco as modulators of neuronal nitric oxide synthase activity.

Venkatakrishnan P, Gairola CG, Castagnoli N Jr, Miller RT.

Phytother Res. 2009 Dec;23(12):1663-72. doi: 10.1002/ptr.2789.

13.

Inhibition of monoamine oxidase by (E)-styrylisatin analogues.

Van der Walt EM, Milczek EM, Malan SF, Edmondson DE, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. doi: 10.1016/j.bmcl.2009.03.030. Epub 2009 Mar 14.

14.

Inhibition of monoamine oxidase B by N-methyl-2-phenylmaleimides.

Manley-King CI, Terre'Blanche G, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2009 Apr 15;17(8):3104-10. doi: 10.1016/j.bmc.2009.03.005. Epub 2009 Mar 9.

PMID:
19324554
15.

Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Petzer JP, Castagnoli N Jr, Schwarzschild MA, Chen JF, Van der Schyf CJ.

Neurotherapeutics. 2009 Jan;6(1):141-51. doi: 10.1016/j.nurt.2008.10.035. Review.

16.

Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B.

Pretorius A, Ogunrombi MO, Terre'blanche G, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2008 Oct 1;16(19):8813-7. doi: 10.1016/j.bmc.2008.09.001. Epub 2008 Sep 5.

PMID:
18799315
17.

Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.

Pretorius J, Malan SF, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2008 Sep 15;16(18):8676-84. doi: 10.1016/j.bmc.2008.07.088. Epub 2008 Aug 5.

PMID:
18723354
18.

The tert-butoxyl radical mediated hydrogen atom transfer reactions of the Parkinsonian proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and selected tertiary amines.

Suleman NK, Flores J, Tanko JM, Isin EM, Castagnoli N Jr.

Bioorg Med Chem. 2008 Sep 15;16(18):8557-62. doi: 10.1016/j.bmc.2008.08.013. Epub 2008 Aug 7.

PMID:
18713667
19.

Electrochemical mass spectrometric studies on 1-cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Castagnoli N, Bissel P, Jurva U, Ashraf-Khorasani M.

Rapid Commun Mass Spectrom. 2008 Jul;22(13):2089-96. doi: 10.1002/rcm.3592.

PMID:
18523979
20.

Stereochemical studies on the novel monoamine oxidase B substrates (1R,6S)- and (1S,6R)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane.

Bissel P, Khalil A, Rimoldi JM, Igarashi K, Edmondson D, Miller A, Castagnoli N Jr.

Bioorg Med Chem. 2008 Apr 1;16(7):3557-64. doi: 10.1016/j.bmc.2008.02.014. Epub 2008 Feb 8.

PMID:
18313306
21.

Structure-activity relationships in the inhibition of monoamine oxidase B by 1-methyl-3-phenylpyrroles.

Ogunrombi MO, Malan SF, Terre'blanche G, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2008 Mar 1;16(5):2463-72. Epub 2007 Nov 28.

PMID:
18065227
22.

Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.

Ogunrombi MO, Malan SF, Terre'Blanche G, Castagnoli K, Castagnoli N Jr, Bergh JJ, Petzer JP.

Life Sci. 2007 Jul 19;81(6):458-67. Epub 2007 Jun 28.

PMID:
17655878
23.

The first calibration of an aminiumyl radical ion clock: why N-cyclopropylanilines may be poor mechanistic probes for single electron transfer.

Li X, Grimm ML, Igarashi K, Castagnoli N Jr, Tanko JM.

Chem Commun (Camb). 2007 Jul 7;(25):2648-50. Epub 2007 Apr 3.

PMID:
17579767
24.

Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues.

van den Berg D, Zoellner KR, Ogunrombi MO, Malan SF, Terre'Blanche G, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2007 Jun 1;15(11):3692-702. Epub 2007 Mar 18.

PMID:
17416530
25.

Mass spectrometric studies on 4-aryl-1-cyclopropyl-1,2-dihydropyridinyl derivatives: an examination of a novel fragmentation pathway.

Bissel P, Geherin S, Igarashi K, Gandour RD, Lazar IM, Castagnoli N Jr.

J Mass Spectrom. 2006 Dec;41(12):1643-53. Erratum in: J Mass Spectrom. 2007 Apr;42(4):546.

PMID:
17136767
26.

Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design.

Binda C, Hubálek F, Li M, Castagnoli N, Edmondson DE, Mattevi A.

Neurology. 2006 Oct 10;67(7 Suppl 2):S5-7.

PMID:
17030739
27.

Synthesis, structural reassignment, and biological activity of type B MAO inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core.

Frédérick R, Dumont W, Ooms F, Aschenbach L, Van der Schyf CJ, Castagnoli N, Wouters J, Krief A.

J Med Chem. 2006 Jun 15;49(12):3743-7.

PMID:
16759116
28.

Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.

Khalil AA, Davies B, Castagnoli N Jr.

Bioorg Med Chem. 2006 May 15;14(10):3392-8. Epub 2006 Feb 3.

PMID:
16458520
29.

Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC).

Vlok N, Malan SF, Castagnoli N Jr, Bergh JJ, Petzer JP.

Bioorg Med Chem. 2006 May 15;14(10):3512-21. Epub 2006 Jan 26.

PMID:
16442801
30.

(E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B.

Frédérick R, Ooms F, Castagnoli N Jr, Petzer JP, Feng JF, Schwarzschild MA, Van der Schyf CJ, Wouters J.

Acta Crystallogr C. 2005 Sep;61(Pt 9):o531-2. Epub 2005 Aug 10.

PMID:
16143772
31.

Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines.

Jurva U, Bissel P, Isin EM, Igarashi K, Kuttab S, Castagnoli N Jr.

J Am Chem Soc. 2005 Sep 7;127(35):12368-77.

PMID:
16131218
32.

A novel and selective monoamine oxidase B substrate.

Rimoldi JM, Puppali SG, Isin E, Bissel P, Khalil A, Castagnoli N Jr.

Bioorg Med Chem. 2005 Oct 15;13(20):5808-13.

PMID:
15993094
33.

Studies on the cytochrome P450 catalyzed oxidation of 13C labeled 1-cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine by 13C NMR.

Bissel P, Castagnoli N Jr, Penich S.

Bioorg Med Chem. 2005 Apr 15;13(8):2975-80. Erratum in: Bioorg Med Chem. 2005 Jul 15;13(14):4588. Bioorg Med Chem. 2005 Jun 2;13(12):4130. Penich, Sarah [added].

PMID:
15781407
34.

Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors.

Hubálek F, Binda C, Khalil A, Li M, Mattevi A, Castagnoli N, Edmondson DE.

J Biol Chem. 2005 Apr 22;280(16):15761-6. Epub 2005 Feb 14.

35.

Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration.

Castagnoli K, Petzer JB, Steyn SJ, van der Schyf CJ, Castagnoli N Jr.

Inflammopharmacology. 2003;11(2):183-8.

PMID:
15035820
36.

Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.

Castagnoli N Jr, Petzer JP, Steyn S, Castagnoli K, Chen JF, Schwarzschild MA, Van der Schyf CJ.

Neurology. 2003 Dec 9;61(11 Suppl 6):S62-8.

PMID:
14663013
37.

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr, Chen JF.

Neurology. 2003 Dec 9;61(11 Suppl 6):S55-61. Review.

PMID:
14663012
38.

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.

Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN.

Exp Neurol. 2003 Nov;184(1):285-94.

PMID:
14637099
39.

Synthesis and in vitro biological evaluation of fluoro-substituted-4-phenyl-1,2,3,6-tetrahydropyridines as monoamine oxidase B substrates.

Beeler AB, Gadepalli RS, Steyn S, Castagnoli N, Rimoldi JM.

Bioorg Med Chem. 2003 Nov 17;11(23):5229-34.

PMID:
14604687
40.

Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.

van der Schyf CJ, Castagnoli K, Palmer S, Hazelwood L, Castagnoli N Jr.

Neurotox Res. 2000 Apr;1(4):261-9.

PMID:
12835094
41.

Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase.

Castagnoli K, Steyn SJ, Magnin G, Van Der Schyf CJ, Fourie I, Khalil A, Castagnoli N Jr.

Neurotox Res. 2002 Mar;4(2):151-60.

PMID:
12829416
42.

Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations.

Usuki E, Bloomquist JR, Freeborn E, Casagnoli K, Van Der Schyf CJ, Castagnoli N Jr.

Neurotox Res. 2002 Feb;4(1):51-8.

PMID:
12826493
43.

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.

Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N.

Bioorg Med Chem. 2003 Apr 3;11(7):1299-310.

PMID:
12628657
44.

Rational approaches towards reversible inhibition of type B monoamine oxidase. Design and evaluation of a novel 5H-Indeno[1,2-c]pyridazin-5-one derivative.

Ooms F, Frédérick R, Durant F, Petzer JP, Castagnoli N, Van der Schyf CJ, Wouters J.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):69-73.

PMID:
12467619
45.

Studies on the oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines.

Castagnoli N Jr, Castagnoli K, Magnin G, Kuttab S, Shang J.

Drug Metab Rev. 2002 Aug;34(3):533-47. Review.

PMID:
12214665
46.

8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.

Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N Jr, Schwarzschild MA.

J Biol Chem. 2002 Sep 27;277(39):36040-4. Epub 2002 Jul 18.

47.

Synthesis and biological evaluation of MAO-A selective 1,4-disubstituted-1,2,3,6-tetrahydropyridinyl substrates.

Bissel P, Bigley MC, Castagnoli K, Castagnoli N Jr.

Bioorg Med Chem. 2002 Sep;10(9):3031-41.

PMID:
12110326
48.

Enhancement of auditory sensory gating and stimulus-bound gamma band (40 Hz) oscillations in heavy tobacco smokers.

Crawford HJ, McClain-Furmanski D, Castagnoli N Jr, Castagnoli K.

Neurosci Lett. 2002 Jan 14;317(3):151-5.

PMID:
11755262
49.

Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors.

Kalgutkar AS, Dalvie DK, Castagnoli N Jr, Taylor TJ.

Chem Res Toxicol. 2001 Sep;14(9):1139-62. Review. No abstract available.

PMID:
11559028
50.

Supplemental Content

Loading ...
Support Center